HSHabiba Tariq Saeed

Habiba Tariq Saeed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Habiba Tariq Saeed has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Measurements and management of multiple sclerosis-related fatigue: an umbrella review and meta-analysis

    by Yousef Hawas, Ahmed Abdelmageed, Mohamed Abouzid, Abdallah Ashraf Hamad, Mohamed El-Moslemani, Habiba Tariq Saeed, Esraa Y. Salama, Mohammad Al Diab Al Azzawi, Dalia Kamal Ewis, Abdelfattah Arafa, et al.

    Multiple sclerosis (MS) is an autoimmune-mediated disorder of the central nervous system (CNS) where inflammation, demyelination, and neurodegeneration occur [1]. It is considered the most common n...

  • Therapeutic effects of cannabinoids on Parkinson’s disease: an updated systematic review and meta-analysis of randomized controlled trials

    by Mark Messak, Ahmed Abdelmageed, Ahmed Noureldeen Abbas, Youssef Mandour, Ahmed Talkhan, Mahmoud Fadel Eltohami, Dua’A Kanaan, Fawaz K. Alfahmi, Habiba Tariq Saeed, Lara Hamzeh Hamzeh, et al.

    Current treatments for Parkinson's disease (PD) are primarily symptomatic and may lead to motor fluctuations and levodopa-induced dyskinesia over time, highlighting the need to repurpose other medications. Cannabinoids have gained attention as potential repurposed treatments. This systematic review and meta-analysis evaluated their efficacy in PD while addressing limitations of previous reviews, including low statistical power and inclusion of cannabinoid antagonists in pooled analyses. A literature search was conducted through PubMed, Scopus, and Web of Science, identifying randomized controlled trials (RCTs) evaluating the use of cannabinoids in PD. Quality assessment was done via RoB-2. A random-effects meta-analysis was performed using the meta and metafor packages in R, with mean differences (MD) or standardized mean differences (SMD; Hedges' g) reported with 95% confidence interval (CI). A sensitivity analysis was carried out to assess the robustness of our findings. In crossover trials, effect sizes and standard errors were extrapolated from the reported CIs, considering the paired design. Eleven RCTs were identified, six of which were eligible for meta-analysis due to the absence of poolable outcomes in the remainder. Cannabinoids did not significantly improve PD severity (SMD = 0.16, 95% CI[-0.13 to 0.44], p = 0.27, I²=0%), motor examination (SMD=-0.08, 95% CI[-0.35 to 0.20], p = 0.57, I²=0%), motor experiences of daily living (SMD=-0.08, 95% CI[-0.49 to 0.33], p = 0.71, I²=0%), non-motor symptoms (SMD= -0.03, 95% CI[-0.72 to 0.67], p = 0.94, I²= 64.3%). Sensitivity analysis excluding Peball et al. showed that the pooled estimate of non-motor symptoms was largely driven by nabilone (SMD = 0.34, 95%CI [-0.19 to 0.88], p = 0.21, I²=0%), suggesting a drug-specific benefit signal. Cannabinoids have not shown significant benefit in PD; however, our findings should be interpreted with caution. The nabilone benefit signal for non-motor symptoms represents a distinct question warranting dedicated trials. Future studies should use standardized, pharmacologically stratified protocols.